Deliver Your News to the World

CybeRelease: (OTC: AMZB) Develops Next-Generation Anti-Viral AIDS Drug Formula


(CybeRelease, October 10, 2006) - Lake Harmony, PA - Amazon Biotech, Inc. (OTC BB: AMZB) (Frankfurt: B2D.F) announced that it has developed a next-generation AIDS formulation which includes both immune modulator functions and anti-viral activity.
This formulation, based on Amazon’s Phase I/II developmental drug AMZ0026, includes additional active ingredients found in a plant, which are known in the literature to pose anti-viral properties.

The entire formulation is comprised of whole plant pharmaceuticals, in line with Amazon Biotech’s treatment philosophy. Amazon is now pursuing relevant intellectual property protection and IND (Investigational New Drug application) status from the FDA for this novel formulation. Dr. Mechael Kanovsky, President of Amazon Biotech, said, “We are excited to have reached this stage of development with this promising therapeutic agent.”

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company’s first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

For a Free Newsletter and more information, go to

To read the complete release, go to

CybeRelease Gainers are Acorda Therapeutics, Inc. (Nasdaq: ACOR), OMNI Energy Services Corp. (Nasdaq: OMNI), Generex Biotechnology Corporation (Nasdaq: GNBT), ImClone Systems Incorporated (Nasdaq: IMCL), Amkor Technology, Inc. (Nasdaq: AMKR), Finisar Corporation (Nasdaq: FNSR), CDC Corporation (Nasdaq: CHINA) and Anglo American plc (Nasdaq: AAUK).

CybeRelease Decliners are Express Scripts, Inc. (Nasdaq: ESRX), Dynavax Technologies Corporation (Nasdaq: DVAX), Shire PLC (Nasdaq: SHPGY), ValueClick, Inc. (Nasdaq: VCLK), Matria Healthcare, Inc. (Nasdaq: MATR), Starbucks Corporation (Nasdaq: SBUX), WPP Group PLC (Nasdaq: WPPGY) and Mobility Electronics, Inc. (Nasdaq: MOBE).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A Third Party has hired and paid $500.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.